Chemotherapy use is a significant predictor for sexual dysfunction in women with gynecologic cancer

Blake, Erin A.; Flink, D.M.; Sheeder, Jeanelle; Carrubba, A.R.; Moroney, Marisa R.; Whitmore, G. E.; Guntupalli, Saketh R.

doi:10.1016/j.ygyno.2016.04.463

Cited by 3 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the prevalence of FSD among gynecologic cancer survivors was nearly 90%. Our FSD percentage in this study is similar to earlier studies in Western countries 10,11,16,17 . Interestingly, this result is unexpectedly high when compared to the previous study in the Thai population.…”

Section: Discussionsupporting

confidence: 90%

“…Prior studies found that cancer-related treatment was related to FSD, such as chemotherapy or radiotherapy. 11,24 In one study where a sexual health survey was obtained from 606 cervical cancer patients treated with radiotherapy, there were significantly higher vaginal morbidities than in the control group, leading to sexual and psychological distress. 27 Regarding our results, however, we did not find a correlation between the type of cancer-related treatment and FSD.…”

Section: Discussionmentioning

confidence: 99%

“…The sample size was calculated by nQuery Advisor 6.0 (Statistical Solutions Ltd, Cork, Ireland). The number required in this study came from Zα 2 P (1 À P)/d 2 (Zα was set as 1.96 with type I error of 5%, d was set at 10%, P was obtained from the prevalence of a 0.49 of FSD from the study of Blake et al 11 ). With a 5% increase to compensate for missing or incomplete data, the final sample size was 100 participants.…”

Section: Sample Size Calculation and Data Analysismentioning

confidence: 99%

“…The prevalence of FSD ranges from 30% to 90% in gynecologic cancer survivors with active sexual activities 1,3,5,10,11 . However, the prevalence of FSD might be underrated because women often feel uncomfortable or embarrassed to discuss sexuality problems with their healthcare providers 1 .…”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of FSD ranges from 30% to 90% in gynecologic cancer survivors with active sexual activities. 1,3,5,10,11 However, the prevalence of FSD might be underrated because women often feel uncomfortable or embarrassed to discuss sexuality problems with their healthcare providers. 1 This problem has been abandoned during cancer treatment and follow-up because it is a sensitive issue in individual races, cultures, and religions, especially in Asian women.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Sexual dysfunction in Thai gynecologic malignancies survivors: A single‐institutional cross‐sectional observational survey

Dandamrongrak

Chaiwong

Ekalaktam

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Objective: To examine the prevalence of female sexual dysfunction (FSD) in gynecologic cancer survivors. Methods: A cross-sectional observation survey recruited women aged 18-65 years old who were diagnosed with gynecologic cancers and underwent surgery, radiation, chemotherapy, or combined modalities. Data were collected from September 2019 to March 2020 by the Thai version of the female sexual function index questionnaire to define FSD. The survey contained six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Results: Of the 98 women included in the study, the mean age was 48.7 AE 10.6 years old. Two-third (67.3%) of the participants was premenopausal, had been diagnosed with ovarian cancer, and had early-stage gynecologic cancers. Fifty-eight of 98 (59.2%) participants were sexually active in the past 4 weeks before the survey. Among those, 89.6% had FSD. The median scores in the FSD group were significantly lower than those in the non-FSD group in all six domains, namely, desire, arousal, lubrication, orgasm, satisfaction, and pain (p < 0.05). There was no statistically significant difference observed between participants with and without FSD in terms of age group, cancer-related data, or sexual behavior data, except participants who had good/ excellent relationships with their partners, which impacted FSD (p = 0.01). Conclusions: This study discovered the high prevalence (89.6%) of hidden issue of "female sexual dysfunction" in Thai gynecologic cancer survivors. The good/excellent relationships with their partners affected the FSD who were sexually active in the past 4 weeks before the survey.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Sample Size Calculation and Data Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sexual dysfunction in Thai gynecologic malignancies survivors: A single‐institutional cross‐sectional observational survey

Dandamrongrak

Chaiwong

Ekalaktam

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

Improving Sexual Health Across the Life Span Through Integrated Care in Obstetrics and Gynecology

Hunter,

Pettigrew,

Carpenter

et al. 2024

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Sexual health is a vital part of physical, emotional, and relational well-being among adults across the life span. While patients are reluctant to discuss their sexual concerns, Obstetrics and Gynecology providers are especially well positioned to improve sexual functioning and satisfaction through screening, education, prevention and early intervention, treatment, and integrating behavioral health and sexual medicine services in their clinical practices. This article sets out to provide applied information and perspectives to foster the development of interprofessional sexual medicine services in Obstetrics and Gynecology practices in hospital and community settings.

show abstract

Translation and validation of Persian version of sexual function: vaginal changes questionnaire (SVQ) for women with gynecologic cancers

2022

View full text Add to dashboard Cite

Background Changing in the sexual function is an important condition in women with gynecological cancers. A valid and reliable questionnaire is required to assess this condition. The aim of this study was to translate and validate the Persian version of the Sexual-Vaginal Function Changes Questionnaire (SVQ) in women with gynecologic cancers. Methods This methodological study with a psychometric design was conducted on 250 women with gynecologic cancers, who visited public and private medical centers in Tehran to receive follow-up services. Convenience sampling was conducted from April 2019 to May 2020. First, the Persian version of the Sexual Function-Vaginal Changes Questionnaire was developed and then, psychometric properties such as content validity, face validity, construct validity and criterion validity were assessed. Reliability of the instrument was assessed by Cronbach's alpha coefficient. Results Mean age of participants was 53.3 ± 11.8 and mean score of SVQ was 63.0 ± 9.1 in the possible range of 26–104. Content validity was tested through qualitative method and six items were revised as suggested by the expert panel. Cronbach's alpha coefficient was 0.71 for the whole questionnaire and it was 0.93, 0.92, 0.89, 0.78, 0.88 and 0.78 for the 6 subscales, respectively, which shows the optimal internal consistency. Results of exploratory factor analysis revealed six factors as (1) intemacy and sexual interst, (2) arousal, (3) changes in intemacy and sexual interst after cancer, (4) vaginal changes after cancer, (5) vaginal bleeding during coitus, (6) and sexual worry and dissatisfaction after cancer. explained 70.09% of the variance observed. Criterion validity test of the questionnaire showed a significant correlation between the total SVQ scores and the total Female Sexual Function Index (FSFI) scores as well as between SVQ dimensions and dimensions of FSFI (P < 0.001). Conclusions The findings from this study indicated that the Persian version of the SVQ is a valid and reliable instrument to assess sexual function-vaginal changes in women with gynecologic cancers.

show abstract

Chemotherapy use is a significant predictor for sexual dysfunction in women with gynecologic cancer

Cited by 3 publications

References 0 publications

Sexual dysfunction in Thai gynecologic malignancies survivors: A single‐institutional cross‐sectional observational survey

Sexual dysfunction in Thai gynecologic malignancies survivors: A single‐institutional cross‐sectional observational survey

Improving Sexual Health Across the Life Span Through Integrated Care in Obstetrics and Gynecology

Translation and validation of Persian version of sexual function: vaginal changes questionnaire (SVQ) for women with gynecologic cancers

Contact Info

Product

Resources

About